



Chemesis International Inc. & Rapid Dose Therapeutics Sign a Definitive Agreement for QuickStrip™ Oral Thin Strips

Rapid Dose Therapeutics provides proprietary oral and non-invasive drug delivery technologies designed for applications of many different types of health products.

October 12, 2018 – Vancouver, BC – Chemesis International Inc. (CSE: [CSI](#)) (OTC: [CADMF](#)) (the “Company” or “Chemesis”), and [Rapid Dose Therapeutics Inc.](#) (“RDT”), a Canadian bio-technology company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes, are proud to announce they have signed a definitive agreement, providing a Managed Strip Service Agreement enabling Chemesis to produce QuickStrips™ infused with cannabis oils.

RDT’s innovative QuickStrip is an easy-to-use, safe and effective oral fast-dissolving drug delivery system, developed in conjunction with McMaster University through the renowned Adronov Research Group, which provides accurate dosing and potency.

Under the terms of the agreement, Chemesis will receive rights to produce, distribute and sell QuickStrip products, with rights for cannabis markets in California. With Chemesis’ state-of-the-art facility, the Company believes this partnership with RDT will further strengthen its position in the California cannabis market, by allowing the Company to use a convenient drug delivery system that can target a variety of consumers and also allow them to use cannabis products in a new way. The Company will continue to position itself to capitalize in this growing market with innovative and effective products.

“RDT is an innovator in the drug delivery world, making this an excellent opportunity for Chemesis,” said CEO of Chemesis, Edgar Montero. “QuickStrip is composed of therapeutic products and they also provide a drug delivery system that is quick, convenient, precise, discrete, convenient for travel, and an alternative for those who have problems swallowing pills. The Company believes it can use this drug delivery system to target a wide range of consumers and we look forward to distributing products in the near future.”

“RDT is pleased to be partnering with Chemesis to provide California’s consumers with a delivery method they can count on that begins the move away from inhalation for dosing therapeutic products” explains Mark Upsdell, CEO of RDT. “Chemesis has developed strategies, partnerships, quality oil production, and distribution channels that will allow QuickStrip to expand rapidly into the California market. We will work directly with Chemesis in developing additional white label partnerships with manufacturers and distributors in California.”

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.

Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products.





Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale.

ON BEHALF OF THE BOARD OF DIRECTORS

Edgar Montero
CEO and Director

INVESTOR RELATIONS:

ir@chemesis.com
www.chemesis.com
[1 \(604\) 398-3378](tel:16043983378)

***Forward-Looking Information:** This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.*

The CSE has not reviewed, approved or disapproved the content of this press release

